Curie Capital is a Life Sciences focused venture capital firm specialized in investing in early-stage companies, supporting talented teams with exciting new medical products.

Curie Capital

Curie Capital BV

Looking to connect with us? Coming week our associate Thom Frielink will be present at the Global Investor Forum (March 27) and Innovation for Health (March 28).

❕Today, Citryll is happy to announce the appointment of Maarten Kraan as our new Chief Medical Officer. 

We are very excited to have Maarten on board! As we begin a new chapter at Citryll, his experience will be invaluable in advancing CIT-013, our lead antibody, into Phase 2a proof-of-concept studies in rheumatoid arthritis and hidradenitis suppurativa.

➡ Take a look at our press release for the full details of this announcement: https://lnkd.in/dNjVwfsq

Curie Capital BV is proud to announce its latest investment: we are honored to continue our commitment to the newly named Flindr (formerly Immagene), as part of their €20 million Series A financing to advance first-in-class small molecule inhibitors. This round is led by V-Bio Ventures with an international syndicate which includes Johnson & Johnson Innovation JJDC Inc, Qbic Fund | Venture Capital, PMV, as well as seed investors Oncode Oncology Bridge Fund, Swanbridge Capital and Brabantse Ontwikkelings Maatschappij (BOM). Flindr (formerly Immagene) discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations. Their lead asset is a first-in-class small molecule inhibitor of the cancer driver RNF31. 

For more information, please see https://lnkd.in/eQ64JYH8

Curie Capital has exciting news from its clinical stage portfolio company #Citryll, developing CIT-013 to treat immune-mediated inflammatory diseases (IMIDs):

We welcome Eduardo Bravo (CEO) and Tim Schenk (CBO), who are joining the great team of Citryll!

https://lnkd.in/exsD57X8

Metric
Company Name	Curie Capital
Symbol
MSH ID	NL:CURIECAPITAL
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	NL
Stage
Employee Count	4
Website	curiecapital.nl
LinkedIn	curie-capital-bv
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CURI

NL:CURIECAPITAL

Curie Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue